Human lactoferrin (hLF), a protein involved in host defence against infection and excessive inflammation, interacts with heparin, the lipid A moiety of bacterial lipopolysaccharide, human lysozyme (hLZ) and DNA. To determine which region of the molecule is important in these interactions, solid-phase ligand binding assays were performed with hLF from human milk (natural hLF) and N-terminally deleted hLF variants. Iron-saturated and natural hLF bound equally well to heparin, lipid A, hLZ and DNA. Natural hLF lacking the first two N-terminal amino acids (Gly1-Arg2) showed reactivities of one-half, two-thirds, one-third and one-third towards heparin, lipid A, hLZ and DNA respectively compared with N-terminally intact hLF. A lack of the first three residues (Gly1-Arg2-Arg3) decreased binding to the same ligands to one-eighth, one-quarter, one-twentieth and one-seventeenth respectively. No binding occurred with a mutant lacking the first five residues (Gly1-Arg2-Arg3-Arg4-Arg5). An anti-hLF monoclonal antibody (E11) that reacts to an N-lobe epitope including Arg5 completely blocked hLF-ligand interaction. These results show that the N-terminal stretch of four consecutive arginine residues, Arg2-Arg3-Arg4-Arg5, has a decisive role in the interaction of hLF with heparin, lipid A, hLZ and DNA. The role of limited N-terminal proteolysis of hLF in its anti-infective and anti-inflammatory properties is discussed.
Skip Nav Destination
Article navigation
November 1997
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Research Article|
November 15 1997
N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA
Patrick H. C. VAN BERKEL;
Patrick H. C. VAN BERKEL
*Leiden Institute of Chemistry, Medical Biotechnology Department, Gorlaeus Laboratories, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
Search for other works by this author on:
E. J. Marlieke GEERTS;
E. J. Marlieke GEERTS
†Pharming BV, Niels Bohrweg 11-13, 2333 CA, Leiden, The Netherlands
Search for other works by this author on:
A. Harry VAN VEEN;
A. Harry VAN VEEN
†Pharming BV, Niels Bohrweg 11-13, 2333 CA, Leiden, The Netherlands
Search for other works by this author on:
Mathias MERICSKAY;
Mathias MERICSKAY
1
*Leiden Institute of Chemistry, Medical Biotechnology Department, Gorlaeus Laboratories, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
Search for other works by this author on:
A. Herman DE BOER;
A. Herman DE BOER
*Leiden Institute of Chemistry, Medical Biotechnology Department, Gorlaeus Laboratories, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
Search for other works by this author on:
H. Jan NUIJENS
H. Jan NUIJENS
2
†Pharming BV, Niels Bohrweg 11-13, 2333 CA, Leiden, The Netherlands
2To whom correspondence should be addressed.
Search for other works by this author on:
Biochem J (1997) 328 (1): 145–151.
Article history
Received:
May 02 1997
Revision Received:
July 16 1997
Accepted:
July 23 1997
Citation
Patrick H. C. VAN BERKEL, E. J. Marlieke GEERTS, A. Harry VAN VEEN, Mathias MERICSKAY, A. Herman DE BOER, H. Jan NUIJENS; N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem J 15 November 1997; 328 (1): 145–151. doi: https://doi.org/10.1042/bj3280145
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.